Profil
Ian Wilson is currently the Chief Executive & Operating Officer at ImaginAb, Inc. He previously served as the Chief Executive & Technology Officer at Edinburgh Molecular Imaging Ltd.
from 2015 to 2018.
Postes actifs de Ian Wilson
Sociétés | Poste | Début |
---|---|---|
ImaginAb, Inc.
ImaginAb, Inc. Medical SpecialtiesHealth Technology ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA. | Directeur Général | 26/02/2019 |
Anciens postes connus de Ian Wilson
Sociétés | Poste | Fin |
---|---|---|
Edinburgh Molecular Imaging Ltd.
Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | Directeur Général | 01/02/2018 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Edinburgh Molecular Imaging Ltd.
Edinburgh Molecular Imaging Ltd. Medical SpecialtiesHealth Technology Edinburgh Molecular Imaging Ltd. develops optical molecular imaging technology, which includes optical imaging, cancer imaging and lung imaging. The firm's molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. The company was founded by Chris Haslett, Kev Dhaliwal and Mark Bradley in February 2014 and is headquartered in Edinburgh, the United Kingdom. | Health Technology |
ImaginAb, Inc.
ImaginAb, Inc. Medical SpecialtiesHealth Technology ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA. | Health Technology |